Medical cannabis and neurological disorders: a clinical overview

Author:

Erridge Simon1,Sodergren Mikael H1

Affiliation:

1. Medical Cannabis Research Group, Imperial College London and Sapphire Medical Clinics, London

Abstract

In the UK, in addition to licensed medical cannabis products, over 30 000 patients are prescribed unlicensed preparations. The conditions for which these unlicensed products are commonly prescribed and have been identified as having potential therapeutic value, include neurological conditions, as well as those conditions that require modulation of the central and/or peripheral nervous system via targeting the endocannabinoid system, such as during chronic pain. Considering the growing evidence base, this article examines some of the pre-clinical and clinical rationale underpinning the increase in the prescription of these products since their rescheduling in 2018. Beyond this, the article outlines the regulatory environment for prescribing, some of the barriers that patients face, and the work of Sapphire Medical Clinics to uphold stringent clinical governance practices, while providing a patient-centred service.

Publisher

Mark Allen Group

Subject

Neurology (clinical),General Nursing

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3